Loss of HES1 expression is associated with extracellular matrix remodeling and tumor immune suppression in KRAS mutant colon adenocarcinomas
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Loss of HES1 expression is associated with extracellular matrix remodeling and tumor immune suppression in KRAS mutant colon adenocarcinomas ; volume:13 ; number:1 ; day:25 ; month:9 ; year:2023 ; pages:1-13 ; date:12.2023
Scientific reports ; 13, Heft 1 (25.9.2023), 1-13, 12.2023
- Urheber
-
Wang, Lei
Gu, Wenchao
Zou, Bingqing
Kalady, Matthew
Xin, Wei
Zhou, Lan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-42234-7
- URN
-
urn:nbn:de:101:1-2024020710384293064043
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wang, Lei
- Gu, Wenchao
- Zou, Bingqing
- Kalady, Matthew
- Xin, Wei
- Zhou, Lan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Targeting a defective DNA damage response in KRAS-mutant adenocarcinomas
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Targeting mutant KRAS in pancreatic cancer: futile or promising?
Targeting a defective DNA damage response in KRAS-mutant adenocarcinomas
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Targeting mutant KRAS in pancreatic cancer: futile or promising?
Targeting a defective DNA damage response in KRAS-mutant adenocarcinomas
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression